clinical trial · NCT05268614
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal Squamous Cell CarcinomaRadiation therapyCisplatin
brief summary
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
started
May 16, 2022
primary completion
Jun 1, 2029
completion
Jun 1, 2032
last updated
Apr 24, 2026
official title
Risk Adapted De-Intensification of Radio-Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma Based on HPV Subtype and Plasma Circulating Free HPV DNA Level and Clearance Rate
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol